Zealand Pharma Hires Vertex Veteran to Lead Investor Relations Amid Pipeline Push
Event summary
- Eric Rojas joins Zealand Pharma as VP of Investor Relations, effective April 15, 2026.
- Rojas brings 20+ years of experience from Vertex Pharmaceuticals and Shire (acquired by Takeda for $62B).
- Appointment coincides with Zealand's expansion into Cambridge, Massachusetts.
- Zealand has three late-stage drug candidates in development for obesity and metabolic health.
The big picture
Zealand Pharma's hire of a seasoned IR executive from Vertex underscores its ambition to elevate market visibility during a critical phase of drug development. The move comes as the company positions itself as a leader in obesity and metabolic health, leveraging peptide R&D and AI-driven data platforms. With three candidates in late-stage trials and a $62B acquisition precedent from Rojas' past employer Shire, Zealand is signaling confidence in its pipeline's transformative potential.
What we're watching
- Pipeline Momentum
- Whether Zealand can translate its late-stage candidates into commercial success.
- Investor Confidence
- How Rojas' experience will shape investor perception during catalyst-rich periods.
- Geographic Expansion
- The pace at which Zealand's new Cambridge site accelerates U.S. market penetration.
Related topics